Harmony Biosciences Holdings Inc. (HRMY) earns a Roarable Rating of A (Strong Buy) with 86/100 RQD Confidence. High-quality cash engine (77.2% gross margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $37.91 (-2.19% 1D, market cap $2.26B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 18/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, HRMY ranks #3 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable A (86/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B) and HCM (HUTCHMED (China) Limited) posts a E grade (34/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.29B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).
Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77.2% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 40.1% FCF Margin ($347.9M FCF) & 77.2% Gross Margin
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)
Even with a 86/100 (A) score, HRMY faces multiple-compression risk if 14.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 74.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($39.78) or 200D SMA ($34.71) invalidates the momentum regime and cuts Target Base ($42.69) toward Bear Floor ($31.09).
Harmony Biosciences Holdings Inc. (HRMY) dropped -2.19% to $37.91, trading at 68% of its 52-week range ($25.9 – $43.49). High-quality cash engine (77.2% gross margin, 63% return on capital) with steady institutional support.
Yahoo! Finance Canada report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HRMY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HRMY. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Harmony Biosciences Holdings Inc. (HRMY) ranks #3 by composite RQD confidence (86/100, grade A) and #234 by equity capitalization ($2.26B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently leads its immediate peer cohort in composite quantitative strength at 86/100 (A).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HRMY
ACTIVE
Harmony Biosciences Holdings Inc. | A | 86/100 | 14.2x | 77.2% | 63.0% | -2.19% | $2.26B | Benchmark Subject |
| VERA Vera Therapeutics Inc. (Class A) | E | 31/100 | — | — | -35.0% | -2.36% | $2.23B | /vera-vs-hrmy → |
| HCM HUTCHMED (China) Limited | E | 34/100 | 5.2x | — | -2.5% | +0.91% | $2.29B | /hcm-vs-hrmy → |
| XNCR Xencor Inc. | D | 47/100 | — | — | -21.3% | -0.54% | $2.22B | /xncr-vs-hrmy → |
| AUPH Aurinia Pharmaceuticals Inc | B | 74/100 | 8.0x | 88.5% | 16.5% | -3.06% | $2.22B | /auph-vs-hrmy → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harmony Biosciences Holdings Inc. (HRMY) reported GAAP revenue of $868.5M (+21.5% vs. FY2024 revenue of $714.7M , and +49.2% cumulative change since FY2023) , GAAP net income of $158.7M, operating cash flow of $348.2M, and free cash flow of $347.9M (+59.1% YoY). On the balance sheet, HRMY closed FY2025 with $1.27B in total assets against $143.7M in total debt (Altman Z-Score: 5.38, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $868.5M | $158.7M | $348.2M | $347.9M | $1.27B | $143.7M |
| FY2024 (FY) | 2024-12-31 | $714.7M | $145.5M | $219.8M | $218.7M | $999.2M | $163.0M |
| FY2023 (FY) | 2023-12-31 | $582.0M | $128.9M | $219.4M | $219.4M | — | — |
As of 2026-11-03, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $37.91 (-2.19% 1D, market cap $2.26B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 18/20, and Executive Insider Alignment 19/20. Across 1015 tracked Health Care issuers, HRMY ranks #3 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable A (86/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B) and HCM (HUTCHMED (China) Limited) posts a E grade (34/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.29B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).
Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77.2% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
HRMY last traded at $37.91 (-2.19% on volume of 994,027 shares), positioning the stock -4.70% below its 50-day simple moving average ($39.78) and +9.22% above its 200-day simple moving average ($34.71). Across its 52-week range of $25.90 to $43.49, HRMY sits at the 68.3% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($34.80 to $41.02).
Harmony Biosciences Holdings Inc. (HRMY) earns a live Roarable RQD composite score of 86/100, corresponding to a A letter grade (Roarable Strong Buy) at a spot price of $37.91 (-2.19% 1D, market capitalization $2.26B).
Harmony Biosciences Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $2.2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Harmony Biosciences Holdings Inc. (HRMY) reported $868.5M in annual revenue (up from $714.7M in FY2024, +21.5% YoY) and $158.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($582.0M revenue, $128.9M net income) through FY2025, HRMY scaled operating cash flow to $348.2M and free cash flow to $347.9M, backed by $1.27B in total assets against $143.7M in total debt.
For a prospective investor, the second-order items the source does raise are the leadership transition and the patent ruling referenced in the news feed; their timing and magnitude are not resolved by the data.
Real-time company headlines, analyst actions, and sector developments for Harmony Biosciences Holdings Inc. (HRMY) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.
Cash generation is exceptional, with FY 2025 FCF of $347.9M, an FCF yield of 15.48%, and ROIC of 63%.. When you look under the hood at HRMY, Fundamental Cash Engine is 20/20 with 77.2% gross margins and 63.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (11/20) has been quietly accumulating below $43.49. My 12M target is $49.23.
@MultipleCompression Shorting a 11/20 institutional whale-flow stock at $38.76 is dangerous when funds are rotating into Health Care.
Here is the bear case nobody on the bull side wants to address on HRMY: A pending patent ruling and a CEO transition are flagged in the news feed, and institutional flow scores only 11/20.. At 14.2x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: